Abstract
Background Coronavirus disease 19 (COVID-19) has become a global unprecedented pandemic infecting more than one millon people, which is declared by WHO as a international public health emergency. Eosinopenia may predict a poor prognosis of COVID-19. However, to date, there is no detailed analysis of the clinical characteristics of COVID-19 patients with eosinopenia.
Research question The aim of this study was to describe clinical characteristics of COVID-19 patients with eosinopenia.
Study Design and Methods This was a multi-center retrospective study conducted in three tertiary hospitals. A total of 59 patients with COVID-19 were reviewed from January 23, 2020 to March 10, 2020. We described clincial characteristics of patients with COIVD-19 and eosinopenia phenotype.
Results The median age of patients with COVID-19 was 39 years old, and 32 (54,2%) were male. Patients with severe type had higher proportions of dyspnea (50%) and gastrointestinal symptoms (50%) compared with mild or moderate patients. Laboratory findings indicated that lower counts of lymphocyte and eosnophils were observed in patients with severe type. Cough, sputum, and fatigue were more common symptoms in eosinopenia patients compared with non-eosinopenia patients. High proportion of comorbidities was observed in eosinopenia patients. Laboratory findings indicated that lymphocyte counts (median: 101 cells/μl) in eosinopenia patients were significantly less than those of non-eosinopenia patients (median: 167 cells/μl, p<0.001). The use of corticosteroids therapy in COVID-19 patients with eosinopenia were notably higher than those in patients with non-eosinopenia (50% vs 13.8%, respectively, p=0.005). Compared with parameters in non-eosinopenia patients, eosinopenia patients were more inclined to have less lymphocyte counts (OR value 6.566, 95%CI[1.101-39.173], p=0.039).
Interpretation Eosinopenia are very common in COVID-19 patient, particularly in severe patients. Common symptoms included fever, cough, sputum, and fatigue are frequent in eosinopenia patients. Eosinopenia may represent a novel phenotype in COVID-19, which needs further investigation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The design of the study and collection, analysis, and interpretation of data were supported by Anhui Provincial Key projects of Natural Science Foundation for Colleges and Universities (KJ2017A264), and Key projects of science and technology for prevetion and control of COVID-19 in Wuhu City (2020dx1-1, 2020dx1-3, and 2020dx2-1).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Co-authors email addresses: Yusheng Cheng (chengys1222{at}126.com), Yun Zhou (18055316887{at}163.com), Mengde Zhu (zmd19830926{at}163.com), Lei Zha (lei.zha{at}liverpool.ac.uk), Zhiwei Lu (sduzhiwei{at}sina.com), Zhen Ding (imdzh{at}163.com), Jianghua Yang (yjhpath{at}163.com), Gang Yang (13855306767{at}163.com)
Consent for publication Not applicable.
Competing interests The authors declare that they have no competing interests.
Data Availability
CY, ZY, ZM, ZL, LZ, DZ, YJ and YG contributed to the concept and design, analysis and interpretation as well as manuscript drafting. All authors read and approved the final manuscript.
